Everything below concerns half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-15. Numbers and descriptions here follow the published literature rather than marketing material.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
=== Elderly === In older people, Z-drugs increase the risk of fractures and falls. The 2023 Beers criteria lists all three Z-drugs approved in the US (zolpidem, zaleplon, eszolpiclon) as unsuitable for older people. Z-drugs causes impairments in body balance and standing steadiness in individuals who wake up at night or the next morning. Falls and hip fractures are frequently reported. The combination with alcohol consumption increases these impairments. Partial, but incomplete tolerance develops to these impairments. Z-drugs increase postural sway and increases the number of falls in older people, as well as cognitive side effects. Falls are a significant cause of death in older people.
=== Pharmacodynamics === In rabbits, 2,3-dihydro-LSD had about 4% (1/25th) of the potency of LSD in inducing hyperthermia, while in mice, it was "equally toxic" (presumably referring to LD50Tooltip median lethal dose) as LSD.
== Early life and education == Scrutton was born in Batley, West Riding of Yorkshire and was brought up in Cleckheaton where he went to Whitcliffe Mount School. Scrutton graduated from King's College London with a first class Bachelor of Science degree in Biochemistry in 1985. He was a Benefactors' Scholar at St John's College, Cambridge where he completed his doctoral research (PhD) in 1988 supervised by Richard Perham. He was a Research Fellow of St John's College, Cambridge (1989–92) and a Fellow / Director of Studies at Churchill College, Cambridge (1992–95). He was awarded a Doctor of Science (ScD) degree in 2003 by the University of Cambridge.
Cold fission Fissile material Fission fragment reactor Hybrid fusion/fission Nuclear fusion Nuclear propulsion Photofission HD 101065 – Star in the constellation Centaurus which contain large amount of thorium, uranium and some short-lived radioactive isotopes.
Leumorphin, also known as dynorphin B1–29, is a naturally occurring endogenous opioid peptide. Derived as a proteolytic cleavage product of residues 226-254 of prodynorphin (preproenkephalin B), leumorphin is a nonacosapeptide (29 amino acids in length) and has the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala. It can be further reduced to dynorphin B (dynorphin B-13) and dynorphin B-14 by pitrilysin metallopeptidase 1 (formerly referred to as "dynorphin-converting enzyme"), an enzyme of the endopeptidase family. Leumorphin behaves as a potent and selective κ-opioid receptor agonist, similarly to other endogenous opioid peptide derivatives of prodynorphin.
Sources: en.wikipedia.org
== Natural and synthetic cannabinoids == The following are banned for in-competition use only, with the exception of cannabidiol (CBD) which is not banned for any use. In 2013, the level of THC metabolite allowed was changed from 15 ng/mL to 150 ng/mL so as to only detect in-competition use.
=== Membership policy === WOSM's membership consists of its remaining founding member organizations and organizations recognized by WOSM as national scout organizations. WOSM's rules protect its founding and existing member organizations by permitting only one member organization in each country and locking-out all other Scout organizations from WOSM membership, recognition and participation no matter how worthy or large their membership. Several member organizations are federations, some with different component groups divided on the basis of religion (e.g., France and Denmark), ethnic identification (e.g., Israel) or language (e.g., Belgium). However, WOSM has never required an existing member organization to federate with other Scout organizations in the country, in order to make WOSM more inclusive and representative. There are numerous Canadian Scout organizations but only one is a WOSM member organization (the Canadian branch of one of the organizations that founded WOSM) which has a French language affiliate which is thereby recognized by WOSM. Other than this inherent limitation on WOSM membership, the basis for WOSM membership includes adherence to WOSM's aims and principles and independence from political involvement on the part of each member organization.
Research suggests that graphene filters could outperform other techniques of desalination by a significant margin. In 2021, researchers found that a reusable graphene foam could efficiently filter uranium (and possibly other heavy metals such as lead, mercury and cadmium) from water at the rate of 4 grams of uranium/gram of graphene.
=== Online works by Adorno === Works by or about Theodor W. Adorno at the Internet Archive The Adorno Reference Archive at Marxists.org. Contains complete texts of Enlightenment as Mass Deception, Supramundane Character of the Hegelian World Spirit and Minima Moralia. Negative Dialectics at efn.org.
The cell-extrinsic hallmarks of FLS in RA are: promotes osteoclastogenesis and bone erosion, contributes to cartilage degradation, induces synovial angiogenesis, and recruits and stimulates immune cells.
Sources: en.wikipedia.org
We would be more likely to communicate with highly advanced civilizations that would know and use the laws of physics to a degree that we would not yet be able to understand. Kardashev asserted that "this last point should be taken into account in the research programs of extraterrestrial civilizations" and concluded that it is very likely that our present state is only one of the stages through which every civilization passes during its evolution.
The adoption of -gate to suggest the existence of a scandal was promoted by William Safire, the conservative New York Times columnist and former Nixon administration speechwriter. As early as September 1974, he wrote of "Vietgate", a proposed pardon of the Watergate criminals and Vietnam War draft dodgers. Subsequently, he coined numerous -gate terms, including Billygate, Briefingate, Contragate, Deavergate, Debategate, Doublebillingsgate (of which he later said "My best [-gate coinage] was the encapsulation of a minor ... scandal as doublebillingsgate"), Frankiegate, Franklingate, Genschergate, Housegate, Iraqgate, Koreagate, Lancegate, Maggiegate, Nannygate, Raidergate, Scalpgate, Travelgate, Troopergate, and Whitewatergate. The New York magazine suggested that his aim in doing so was "rehabilitating Nixon by relentlessly tarring his successors with the same rhetorical brush – diminished guilt by association". Safire himself later said to author Eric Alterman that he "may have been seeking to minimize the relative importance of the crimes committed by his former boss with this silliness". The usage has spread into languages other than English; examples of -gate being used to refer to local political scandals have been reported from Argentina, Germany, South Korea, Hungary, Greece and the former Yugoslavia. The term is also used in Mandarin Chinese with the suffix -mén (simplified Chinese: 门; traditional Chinese: 門; lit. 'door', 'gate'). Some commentators have characterized this use of the -gate suffix as a snowclone.
The third case studied here is alpha-methylfentanyl. This group contains a substitution similar to the 3-methylfentanyl that was examined in the previous example on the previous image in this series (Fentanyl Synthesis p4.png), but it is on the phenethyl chain as opposed to being implanted on the piperidine ring. We then mark the two stereocenters, one on the C-4 carbon just as on fentanyl itself, and the other on the C-α (alpha carbon). To analogize these stereocenters we chose N-(1-hydroxyethyl)-4-hydroxypiperidine. When we draw out all potential stereoisomers, we see that the C-4 stereocenter is super-imposable, eliminating it as a true stereocenter. This leaves only 2 R/S assignments that follow the orientation of the stereocenter at the C-α (alpha carbon) position for the real α-methylfentanyl. These are labeled 7S and 7R, a reflection of the stereocenter in the piperidine derivative we used being at C-7 position. It is interesting that the C-4 stereocenter, which has no chiral activity in fentanyl (1st example), activiates it in 3-methylfentanyl with an on-the-ring addition, and loses it again in α-methylfentanyl with an off-the-ring addition. The fourth case studied here is ohmfentanyl. Ohmfentanyl has three potential stereocenters, which are best analogized by another piperidine derivative: N-(1-hydroxyethyl)-3-methyl-4-hydroxypiperidine. This uses a similar structure to analogize the three potential stereocenters in ohmfentanyl, namely the 4-C, the 3-C, and the β-C (beta carbon). These three stereocenters are analogized in the C-4, C-3, and C-7 respectively.
=== Bibliography === Algar, Hamid (1989). "BEKTĀŠĪYA". Encyclopaedia Iranica. Vol. IV. pp. 118–122. Doja, Albert. 2006. "A political history of Bektashism from Ottoman Anatolia to Contemporary Turkey." Journal of Church and State 48 (2): 421–450. doi=10.1093/jcs/48.2.423. Doja, Albert. 2006. "A political history of Bektashism in Albania." Politics, Religion & Ideology 7 (1): 83–107. doi=10.1080/14690760500477919. Elsie, Robert (2001). A Dictionary of Albanian Religion, Mythology and Folk Culture. New York: New York University Press. ISBN 978-1-85065-570-1. Nicolle, David; UK (1995). The Janissaries (5th). Osprey Publishing. ISBN 1-85532-413-X. Muhammed Seyfeddin Ibn Zulfikari Derviş Ali; Bektaşi İkrar Ayini, Kalan Publishing, Translated from Ottoman Turkish by Mahir Ünsal Eriş, Ankara, 2007 Turkish Saggau, Emil BH. "Marginalised Islam: Christianity's role in the Sufi order of Bektashism." In Exploring the Multitude of Muslims in Europe, pp. 183–197. Brill, 2018. Soileau, Mark (2014). "Conforming Haji Bektash: A Saint and His Followers between Orthopraxy and Heteropraxy." Die Welt des Islams 54, pp. 423-459
=== Preadaptation model === The preadaptation model of de novo gene birth uses mathematical modeling to show that when sequences that are normally hidden are exposed to weak or shielded selection, the resulting pool of "cryptic" sequences (i.e. proto-genes) can be purged of "self-evidently deleterious" variants, such as those prone to lead to protein aggregation, and thus enriched in potential adaptations relative to a completely non-expressed and unpurged set of sequences. This revealing and purging of cryptic deleterious non-genic sequences is a byproduct of pervasive transcription and translation of intergenic sequences, and is expected to facilitate the birth of functional de novo protein-coding genes. This is because by eliminating the most deleterious variants, what is left is, by a process of elimination, more likely to be adaptive than expected from random sequences. Using the evolutionary definition of function (i.e. that a gene is by definition under purifying selection against loss), the preadaptation model assumes that "gene birth is a sudden transition to functionality" that occurs as soon as an ORF acquires a net beneficial effect. In order to avoid being deleterious, newborn genes are expected to display exaggerated versions of genic features associated with the avoidance of harm. This is in contrast to the proto-gene model, which expects newborn genes to have features intermediate between old genes and non-genes.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.